Showing results (31-40 of 38) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 38 results.
Therapeutic Advances in Drug Safety|April 29, 2026
The administration of proton pump inhibitors with the CDK4/6 inhibitor abemaciclib does not affect the clinical outcome of metastatic breast cancer patientsStefania Crucitta, Paola Cinacchi, Irene Bargagna, et al.
Journal of Experimental & Clinical Cancer Research : CR|July 2, 2024
Monitoring changing patterns in HER2 addiction by liquid biopsy in advanced breast cancer patientsElena Giordani, Matteo Allegretti, Alberto Sinibaldi, et al.
Breast (Edinburgh, Scotland)|October 25, 2022
Concomitant administration of proton pump inhibitors does not significantly affect clinical outcomes in metastatic breast cancer patients treated with ribociclibMarzia Del Re, Stefania Crucitta, Claudia Omarini, et al.
BMC Cancer|June 15, 2024
Safety and efficacy analysis of neoadjuvant pertuzumab, trastuzumab and standard chemotherapy for HER2-positive early breast cancer: real-world data from NeoPowER studyFabio Canino, Monica Barbolini, Ugo De Giorgi, et al.
Gynecologic Oncology|April 14, 2019
The MITO CERV-2 trial: A randomized phase II study of cetuximab plus carboplatin and paclitaxel, in advanced or recurrent cervical cancerSandro Pignata, Giovanni Scambia, Domenica Lorusso, et al.
Cancer Biology & Therapy|November 8, 2018
A multicenter REtrospective observational study of first-line treatment with PERtuzumab, trastuzumab and taxanes for advanced HER2 positive breast cancer patients. RePer StudyTeresa Gamucci, Laura Pizzuti, Clara Natoli, et al.
Oncotarget|September 17, 2017
A retrospective multicentric observational study of trastuzumab emtansine in HER2 positive metastatic breast cancer: a real-world experiencePatrizia Vici, Laura Pizzuti, Andrea Michelotti, et al.
International Journal of Cancer|July 23, 2019
Distinct HR expression patterns significantly affect the clinical behavior of metastatic HER2+ breast cancer and degree of benefit from novel anti-HER2 agents in the real world settingLaura Pizzuti, Eriseld Krasniqi, Giacomo Barchiesi, et al.
Pageof 4